Satsuma Pharmaceuticals has presented phase 1 data on its second-generation nasal delivery device. The readout positions Satsuma to start a phase 3 clinical trial designed to enable it to bounce back ...
SUNNYVALE, Calif.--(BUSINESS WIRE)-- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced ...
Tuesday, 26 July 2022: Researchers from RCSI University of Medicine and Health Sciences have developed a new lab-based model of a heart and circulatory system that will help test devices to treat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results